Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azimilide.

D Clemett1, A Markham

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 24, 2000
PubMed
Summary
This summary is machine-generated.

Azimilide, a novel potassium channel antagonist, effectively terminates atrial and ventricular arrhythmias by prolonging cardiac repolarization. Clinical studies show its potential in managing atrial fibrillation and supraventricular tachycardia with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiology
  • Electrophysiology

Background:

  • Azimilide is a Class III antiarrhythmic agent.
  • It antagonizes potassium channels, blocking both rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current.
  • This action prolongs cardiac repolarization, increasing action potential duration and effective refractory period.

Purpose of the Study:

  • To evaluate the efficacy and safety of azimilide in treating cardiac arrhythmias.
  • To compare azimilide's antiarrhythmic effects with placebo in clinical settings.
  • To assess azimilide's antifibrillatory properties in animal models.

Main Methods:

  • Animal studies were conducted to assess efficacy in terminating arrhythmias and antifibrillatory effects.

Related Experiment Videos

  • Clinical trials included randomized, double-blind studies in patients with atrial fibrillation/flutter and paroxysmal supraventricular tachycardia.
  • Dosages of oral azimilide (125 mg and 100 mg once daily) were investigated.

    • Main Results:

    • Azimilide demonstrated effectiveness in terminating atrial and ventricular arrhythmias in animal models.
    • In patients with atrial fibrillation/flutter, azimilide (125 mg daily) significantly increased time to recurrence.
    • Azimilide (100 mg daily) showed clinically significant effects in paroxysmal supraventricular tachycardia patients.
    • Headache was the most common adverse event; proarrhythmic events were rare.

    Conclusions:

    • Azimilide is a potent antiarrhythmic agent with a dual mechanism of potassium channel blockade.
    • It shows promise in managing atrial fibrillation, atrial flutter, and supraventricular tachycardia.
    • Azimilide is generally well-tolerated with a low incidence of serious adverse events.